Insights into tumor biology suggest that BRAF mutations contribute to more aggressive disease phenotypes and may influence therapeutic responses, particularly regarding anti-epidermal growth factor receptor antibody treatments in metastatic CRC. Here, EGFR is linked to neoplasm.